2TK.F ELEDON PHARMACEUT.DL-001

Healthcare Biotechnology Frankfurt Exchange
2.42 EUR
Close of Nov 11, 2026
1.17 3.60
Market cap
EUR 197M
P/E
-
P/B
6.91x
ROE
-428.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2TK.F undervalued?

Graham number

The Graham number of ELEDON PHARMACEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ELEDON PHARMACEUT.DL-001 fundamental analysis

No fundamental analysis for ELEDON PHARMACEUT.DL-001 yet.

ELEDON PHARMACEUT.DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ELEDON PHARMACEUT.DL-001

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developin…

Full company profile